Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 6, 2014, Pages 2265-2270

  Lu, Yong ^a   Hong, Bangxing ^a   Li, Haiyan ^a   Zheng, Yuhuan ^a   Zhang, Mingjun ^a   Wang, Siqing ^b   Qian, Jianfei ^a   Yi, Qing ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Adoptive cell therapy; Less exhausted T cells; T cell lineage plasticity

Indexed keywords

ADOPTIVE CELL THERAPY; LESS-EXHAUSTED T CELLS; T-CELL LINEAGE PLASTICITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYCLOPHOSPHAMIDE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-9; MELANOMA, EXPERIMENTAL; MICE;

EID: 84893832325     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1317431111     Document Type: Article

References (35)

1. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12(4):269-281.
2. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21(2):233-240.
3. Rosenberg SA, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-4557.
4. Hinrichs CS, et al. (2009) Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 106(41):17469-17474.
5. Hinrichs CS, et al. (2011) Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3): 808-814.
6. Gattinoni L, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907-912.
7. Hinrichs CS, et al. (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111(11):5326-5333.
8. Hinrichs CS, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114(3):596-599.
9. Shrikant PA, et al. (2010) Regulating functional cell fates in CD8 T cells. Immunol Res 46(1-3):12-22.
10. Ye Z, et al. (2007) Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell Mol Immunol 4(4):277-285.
11. Yu Y, et al. (2013) Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol 190(4): 1873-1881.
12. Garcia-Hernandez MdeL, et al. (2010) Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184(8): 4215-4227.
13. Wang L, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7):1457-1464.
14. Goswami R, Kaplan MH (2011) A brief history of IL-9. J Immunol 186(6):3283-3288.
15. Lu Y, et al. (2012) Th9 cells promote antitumor immune responses in vivo. J Clin Invest 122(11):4160-4171.
16. Purwar R, et al. (2012) Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 18(8):1248-1253.
17. Lu Y, Yi Q (2013) Utilizing TH9 cells as a novel therapeutic strategy for malignancies. OncoImmunology 2(3):e23084.
18. Intlekofer AM, et al. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6(12):1236-1244.
19. Kaplan MH (2013) Th9 cells: Differentiation and disease. Immunol Rev 252(1): 104-115.
20. Lou Y, et al. (2004) Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64(18):6783-6790.
21. Joshi NS, et al. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27(2):281-295.
22. Overwijk WW, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569-580.
23. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155(4):1063-1074.
24. van der Most RG, et al. (2009) Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 4(9):e6982.
25. Hinrichs CS, Gattinoni L, Restifo NP (2006) Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 18(3):363-370.
26. Visekruna A, et al. (2013) Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation. Eur J Immunol 43(3):606-618.
27. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6): 1466-1476.
28. Gattinoni L, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115(6):1616-1626.
29. Takami M, Love RB, Iwashima M (2012) TGF-β converts apoptotic stimuli into the signal for Th9 differentiation. J Immunol 188(9):4369-4375.
30. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6(8):595-601.
31. Liu S, et al. (2010) TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy. J Immunother 33(4):371-381.
32. Böhm W, et al. (1998) T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 161(2):897-908.
33. Baitsch L, et al. (2011) Exhaustion of tumor-specific CD8+ T cells in metastates from melanoma patients. J Clin Invest 121(6):2350-2360.
34. Crespo J, Sun H, Welling TH, Tian Z, Zou W (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25(2): 214-221.
35. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.